Publicacions en què col·labora amb Manuela Igartua Olaechea (107)

2021

  1. GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage

    FASEB Journal, Vol. 35, Núm. 3

2019

  1. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation

    Neurobiology of Disease, Vol. 121, pp. 252-262

  2. GSE4 peptide suppresses oxidative and telomere deficiencies in ataxia telangiectasia patient cells

    Cell Death and Differentiation, Vol. 26, Núm. 10, pp. 1998-2014

  3. Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 18, pp. 101-111

2018

  1. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 145-155

  2. Kosmetika onkologikoa: kimioterapiak eta erradioterapiak larruazalean eragindako efektu desiragaitzak eta horiek tratatzeko konposatu naturaletan oinarritutako formulazio berriak

    Ekaia: Euskal Herriko Unibertsitateko zientzi eta teknologi aldizkaria, Núm. 33, pp. 35-53

  3. Preparation and characterization of resveratrol loaded pectin/alginate blend gastro-resistant Microparticles

    Molecules, Vol. 23, Núm. 8

  4. The role of lipid nanoparticles and its surface modification in reaching the brain: An approach for neurodegenerative diseases treatment

    Current Drug Delivery, Vol. 15, Núm. 9, pp. 1218-1220

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

  2. Nanotechnology based approaches for neurodegenerative disorders: Diagnosis and treatment

    Drug and Gene Delivery to the Central Nervous System for Neuroprotection: Nanotechnological Advances (Springer International Publishing), pp. 57-87

  3. Nanotechnology-based delivery systems to release growth factors and other endogenous molecules for chronic wound healing

    Journal of Drug Delivery Science and Technology, Vol. 42, pp. 2-17

  4. The role of osmolarity adjusting agents in the regulation of encapsulated cell behavior to provide a safer and more predictable delivery of therapeutics

    Drug Delivery, Vol. 24, Núm. 1, pp. 1654

  5. Ultra thin hydro-films based on lactose-crosslinked fish gelatin for wound healing applications

    International Journal of Pharmaceutics, Vol. 530, Núm. 1-2, pp. 455-467

2016

  1. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

    Nanomedicine, Vol. 11, Núm. 10, pp. 1267-1285

  2. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease

    Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230

  3. LL37 loaded nanostructured lipid carriers (NLC): A new strategy for the topical treatment of chronic wounds

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 108, pp. 310-316

  4. Nanoparticle transport across in vitro olfactory cell monolayers

    International Journal of Pharmaceutics, Vol. 499, Núm. 1-2, pp. 81-89

  5. Nanotechnology approaches for skin wound regeneration using drug-delivery systems

    Nanobiomaterials in Soft Tissue Engineering: Applications of Nanobiomaterials (Elsevier Inc.), pp. 31-55

  6. Nanotechnology-based drug-delivery systems releasing growth factors to the CNS: Focusing on neurodegenerative disorders

    Nanobiomaterials in Drug Delivery: Applications of Nanobiomaterials (Elsevier Inc.), pp. 371-402

  7. Nanotherapeutic Platforms for Cancer Treatment: From Preclinical Development to Clinical Application

    Nanoarchitectonics for Smart Delivery and Drug Targeting (Elsevier Inc.), pp. 813-869